clinical trials

Insilico Medicine leverages AI to dramatically accelerate drug candidate development, reducing timelines to around a year, with a record nine months for early discovery. Their generative AI identifies targets and designs molecules, leading to a refined pipeline and faster preclinical nomination. While AI expedites early stages, subsequent clinical trials, manufacturing, and regulatory reviews remain distinct phases. The company has generated 31 preclinical candidates and 13 IND clearances.

Neko Health has secured $700 million in Series C funding, enabling its expansion into the U.S. market with AI-powered preventive health screenings. The company combines advanced imaging, blood tests, sensor technology, and clinician review to detect early health indicators. It plans to launch its first U.S. clinic in New York City. This substantial investment, led by Lightspeed Venture Partners, underscores investor confidence in Neko’s proactive healthcare approach.

BiomX Inc. has issued a statement addressing unusual trading activity in its stock, confirming no undisclosed material developments. The company noted recent challenges, including the discontinuation of a Phase 2b trial, cost-cutting measures, a private placement, and a reverse stock split. Despite a broader biotech sector uptick, BiomX’s shares trade below historical averages. Investor sentiment has closely followed clinical and financial news.

Revelation Biosciences is raising approximately $11 million by exercising outstanding warrants at $0.86 per share. This move also involves issuing new warrants for an additional 26,130,000 shares, contingent on stockholder approval. The capital will support the company’s clinical-stage life sciences operations. This financing strategy, while common, may lead to shareholder dilution. The market’s reaction historically has been mixed to such equity-linked financing.

ONWARD Medical has implanted its investigational ARC-BCI® Therapy in seven individuals, a significant milestone in brain-computer interface technology for spinal cord injury. This system integrates a brain implant, AI for signal decoding, and a neurostimulator to translate intended movement into functional limb motion. The therapy has received FDA Breakthrough Device Designation and is supported by substantial research grants. Further clinical trials are planned to establish broader efficacy and safety.

IDEAYA Biosciences unveiled its 2026 strategic roadmap, focusing on advancing its pipeline. Key objectives include presenting darovasertib trial results for uveal melanoma, potentially supporting accelerated approval, and initiating four registrational trials. The company will also advance its antibody-drug conjugate programs, including IDE849 for neuroendocrine cancers, and explore next-generation therapies targeting MTAP pathway alterations and CDKN2A. With substantial cash reserves extending into 2030, IDEAYA is set for significant pipeline progress and potential regulatory milestones.

AtaiBeckley Inc. has successfully redomiciled its corporate parent from the Netherlands to Delaware, U.S. This strategic move, overwhelmingly approved by shareholders, aims to enhance operational efficiency, streamline corporate structure, and better align with its U.S. investor base. The company’s stock will continue trading on Nasdaq under “ATAI.” This redomiciliation is part of AtaiBeckley’s ongoing reorganization and supports its mission to develop innovative mental health treatments.

.Terns Pharmaceuticals (NASDAQ: TERN) priced an upsized underwritten public offering of 16,250,000 common shares at $40.00 each, generating about $650 million in gross proceeds. Underwriters have a 30‑day option to purchase an additional 2,437,500 shares. The transaction is expected to close on December 11, 2025. Net proceeds will fund research, clinical trials, development, and manufacturing of the lead candidate TERN‑701, support initial launch activities, and cover working‑capital and general corporate needs.